Register for OBR daily


IMS_White_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

DNDN $1.52 0.1300 +9.35%
TGTX $9.93 0.4200 +4.42%
AVEO $1.20 0.0500 +4.35%
MEIP $7.51 0.2900 +4.02%
PVCT $1.12 0.0400 +3.70%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

ENZN $1.43 -0.2200 -13.33%
ARGS $9.10 -0.8100 -8.17%
CYTR $2.97 -0.2600 -8.05%
ARWR $15.22 -1.3100 -7.92%
ONTY $2.06 -0.1750 -7.83%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

Obamacare Effect Linked to Lower Medical Cost Estimates

(Bloomberg) Sept 5, 2014 - Estimates of U.S. health-care spending for the next five years have been lowered by two federal agencies, and the Patient Protection and Affordable Care Act is getting much of the credit.
read article 



New $2.3 Million Workplace Intervention Aims to Reduce Exposure Risk For Oncology Nurses

(U of M Health System) Sept 4, 2014 - Researchers at the University of Michigan School of Nursing and Comprehensive Cancer Center have received a $2.3 million grant to study oncology nurses’ exposure to hazardous drugs, including identifying ways to reduce exposure.
read press release 



Does Owning Cancer Equipment Change Treatment Patterns?

(KevinMD.com blog/Forbes) Sept 4, 2014 - Today’s article follows the money trail to expose a different form of bias: the kind that takes place when doctors own their own diagnostic and therapeutic equipment.
read article 



Optimism in the New Clinical Trials Landscape, Says ACCC 2014 Award Winner

(ACCCBuzz) Sept 4, 2014 - In case you didn’t notice, the cancer clinical trials infrastructure across the country is changing.
read article 



ASH Launches New Publication For Clinicians

(ASH) Sept 4, 2014 - This fall, ASH will begin publishing a monthly news magazine specifically designed to appeal to clinical practitioners in hematology and oncology.
read article 



Is the Network Too Narrow For Hematology?

(ASH) Sept 4, 2014 - Changes from the ACA are putting pressure on insurers. In response, some insurers could start building networks that exclude important hematology services.
read article 



Allen Lichter, CEO of ASCO, Says Big Data, Cost/Value and “-Omics” Will Dominate Oncology in 2030

(UCCC blog) Sept 4, 2014 - Big data, cancer genomics and other “-omics”, and the interplay of cost and value will define the path of cancer research and care for the next 15 years, said Allen S. Lichter, MD, FASCO, CEO of the American Society for Clinical Oncology (ASCO), to a group of about 300 researchers and clinicians gathered for the University of Colorado Cancer Center Fall Retreat 2014.
read article 



OncoMed Moves Forward on Drug Trials Halted Due to Side Effects

(San Francisco Business Times) Sept 4, 2014 - For the second time in a week, the Food and Drug Administration lifted a hold on three early-stage clinical trials of an experimental cancer-fighting drug by OncoMed Pharmaceuticals Inc.
read article 



What's Hot at ASTRO 2014

(Medscape Medical News) Sept 4, 2014 - If submitted abstracts are a sign of the importance and quality of a major scientific congress, then next week's American Society for Radiation Oncology (ASTRO) 56th Annual Meeting is a conference on the upswing.
read article (free registration required) 



Keytruda Cancer Drug Approval Is a Triumph For Merck: R&D Chief Roger Perlmutter on What's Next

(Forbes) Sept 5, 2014 - The next time someone tells you that cancer drug approval is always slow, arduous, and met by huge regulatory snafus, consider this: Merck ’s Keytruda was approved by the U.S. Food and Drug Administration just three-and-a-half years after the first doses of the medicine were given to patients in clinical trials.
read article 



Study IDs Gene Network Behind Untreatable Leukemia and Possible Treatment Target

(Cincinnati Children’s) Sept 4, 2014 - Researchers have identified a genetic/molecular network that fuels a high-risk and aggressive form of Acute Myeloid Leukemia (AML) and its precursor disease Myelodysplastic Syndrome (MDS) – providing a possible therapeutic strategy for an essentially untreatable form of the blood cancer.
read press release 



Stem Cell Transplant With Melphalan Still Preferred in Myeloma

(Medscape Medical News) Sept 4, 2014 - Stem cell transplantation with melphalan is still the preferred treatment for younger patients with multiple myeloma, even in the era of new therapies for the disease, according to a phase 3 trial.
read article (free registration required) 



Common Diabetes Drug Not Linked to Short-Term Risk of Pancreatic Cancer

(UNC Health Care) Sept 4, 2014 - UNC researchers overturn a controversial study about DPP-4 inhibitors – commonly prescribed diabetes medications.
read press release 



A Minimally Invasive, High-Performance Intervention For Staging Lung Cancer

(University of Montreal News [Canada]) Sept 4, 2014 - Endoscopic biopsy of lymph nodes between the two lungs (mediastinum) is a sensitive and accurate technique that can replace mediastinal surgery for staging lung cancer in patients with potentially resectable tumours.
read article 



Lung Cancer Study Reveals New Drug Combination Targets

(ResearchNews@Vanderbilt/Vanderbilt University) Sept 4, 2014 - A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways.
read article 



The Newest Precision Medicine Tool: Prostate Cancer Organoids

(Weill Cornell Medical College) Sept 4, 2014 - Research led by investigators at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College has shown for the first time that organ tissue derived from human prostate cancer tumors can be grown in the laboratory, giving researchers a new tool to test cancer drugs and personalize cancer treatment.
read press release 



Is Soy a Foe to Women With Breast Cancer?

(Philadelphia Inquirer/HealthDay News) Sept 5, 2014 - Soy protein may increase activity in genes linked to breast cancer growth -- at least in certain women who already have the disease, a new study suggests.
read article 



Research Finds No Association Between Wearing a Bra and Breast Cancer

(AACR) Sept 5, 2014 - A population-based case-control study found no association between bra wearing and increased breast cancer risk among postmenopausal women, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
read press release 



New Study: Excellent Outcomes at Five Years With SAVI Breast Brachytherapy Treatment For Early-Stage Breast Cancer

(PRWeb) Sept 4, 2014 - Cianna Medical, Inc., a women’s health company, today announced the release of long-term data supporting the efficacy and safety of breast brachytherapy with the SAVI® applicator.
read press release 



UofL Breast Cancer Researcher Finds Success With Once-Weekly Regimen

(UofL Today/University of Louisville) Sept 4, 2014 - An experimental regimen of once-weekly breast irradiation following lumpectomy provides more convenience to patients at a lower cost, results in better completion rates of prescribed radiation treatment, and produces cosmetic outcomes comparable to the current standard of daily radiation.
read article 



Novel Immunotherapy Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients

(MD Anderson) Sept 5, 2014 - A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence.
read press release 



FDA Approves New Kind of Cancer Drug, Keytruda, For Treating Melanoma

(Washington Post/Associated Press) Sept 4, 2014 - Merck & Co. on Thursday won the first U.S. approval for a new kind of cancer drug that has big advantages over chemotherapy and other older cancer treatments.
read article (free registration required) 



U.S. Approves Merck Immune-Stimulating Drug For Melanoma

(Reuters) Sept 4, 2014 - U.S. regulators on Thursday approved the use of Merck & Co Inc's immuno-oncology drug Keytruda, also known as pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies.
read article 



Study of Jewish Women Shows Link to Cancer Without Family History

(New York Times) Sept 4, 2014 - Women of Ashkenazi Jewish descent who tested positive for cancer-causing genetic mutations during random screenings have high rates of breast and ovarian cancer even when they have no family history of the disease, researchers reported Thursday.
read article 



Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy

(Merck) Sept 4, 2014 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
read corporate press release